Lonza Raises Core Profit Forecast, Fueled by Strong Drug Manufacturing Performance

Switzerland’s Lonza posted 23% growth in its half-year core profit on Wednesday, beating market expectations, driven by a strong performance in its contract drug manufacturing (CDMO) business and contributions from its Vacaville site in the U.S.